STOCK TITAN
  1. Home
  2. News
  3. NRSN

NeuroSense Therapeutics Ltd - NRSN STOCK NEWS

Welcome to our dedicated news page for NeuroSense Therapeutics (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on NeuroSense Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroSense Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroSense Therapeutics's position in the market.

News
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirement. The company has 45 days to submit a plan to regain compliance, with a potential extension of up to 180 days if the plan is accepted. The notification does not immediately affect the listing or trading of NeuroSense's ordinary shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
none
-
News
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) reported a statistically significant 37.4% slowing of disease progression in ALSFRS-R with PrimeC compared to placebo, as revealed in the Phase 2b trial (PARADIGM) evaluation. The trial also showed a strong safety profile and favorable clinical results, with potential partnerships and regulatory meetings expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.94%
Tags
clinical trial
-
News
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) reported positive top-line results from its Phase 2b PARADIGM trial for PrimeC, a drug candidate for ALS. The trial demonstrated a 29% difference in favor of PrimeC in slowing disease progression, with comparable safety and tolerability to placebo. NeuroSense expects to release additional biomarker data in early 2024 and is looking forward to advancing discussions with strategic partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.16%
Tags
clinical trial
News
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) will report new data from the randomized, placebo-controlled, double-blind segment of its ongoing Phase 2b ALS trial of its lead drug candidate PrimeC. The data will include safety, tolerability endpoints, and clinical efficacy outcome measures. The conference call will be held at 8:30 am ET, and the webcast will be available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.16%
Tags
conferences clinical trial
-
News
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) reported topline clinical results from its Phase 2b ALS trial, with a cash runway extending into Q2 2024. The company also confirmed the FDA's CMC strategy for PrimeC, demonstrated PrimeC's outstanding effect on ALS survival, and is preparing for a Phase 2 Alzheimer's disease trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
earnings
-
News
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announces successful Type D meeting with the FDA for PrimeC in ALS treatment, confirming CMC strategy for Phase 3 trial and commercial launch. Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
clinical trial
News
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announces scientific presentations at three upcoming conferences, including the Society of Neuroscience's annual conference and the 34th International Symposium on ALS/MND. The last patient has completed the double-blind segment of PARADIGM, with clinical efficacy results expected in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
-
News
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
Rhea-AI Summary
NeuroSense Therapeutics has completed dosing of the last patient in the double-blind segment of its Phase 2b ALS trial of PrimeC. The company expects to release clinical efficacy results and safety results in December 2023. They also plan to report on the assessment of ALS-biomarkers in H1 2024 and collaborate with Biogen for biomarker analysis. PrimeC has shown promising results in previous trials and has been granted Orphan Drug Designation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.93%
Tags
clinical trial
-
News
NeuroSense Therapeutics to Participate in BIO-Europe Fall
Rhea-AI Summary
NeuroSense Therapeutics Ltd. announced that its Chief Medical Officer, Dr. Ferenc Tracik, will participate in the 29th annual BIO-Europe Fall partnering conference in Munich, Germany. The company's lead drug, PrimeC, is in a global Phase 2b study for ALS, with other programs targeting Alzheimer's and Parkinson's diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
News
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
Rhea-AI Summary
NeuroSense Therapeutics' lead drug candidate, PrimeC, has been confirmed to be effective in treating ALS by a renowned ALS researcher.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
Stock NRSN logo
NeuroSense Therapeutics Ltd

Nasdaq:NRSN

NRSN Rankings

#5104 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NRSN Stock Data

24.96M
10.65M
28.05%
0.91%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Herzliya

About NRSN

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa